Novonesis, the company formed in 2024 through the merger of Novozymes and Chr. Hansen, has expanded its poultry feed enzyme portfolio following the acquisition of the feed enzyme alliance from dsm-firmenich earlier this year.
The acquisition includes the alliance’s product portfolio along with technical and commercial expertise, strengthening Novonesis’s position in the global animal nutrition sector. The company plans to focus on combining enzymes and probiotics to improve poultry performance, health, and welfare.
Novonesis’s current portfolio includes the gut health product Balancius, a range of probiotics, and enzyme products such as phytases, carbohydrases, and proteases for poultry.
The poultry industry continues to face growing pressures from rising feed costs, environmental regulations, and welfare standards. Feed often represents up to 70% of total production costs, making nutrient efficiency a key priority for producers. Enzymes and microbes can play an important role in improving feed conversion, reducing reliance on soya meal, and enhancing nutrient absorption and gut health.
Novonesis has stated that ongoing research and development will remain central to its strategy in supporting future poultry production challenges.